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1-3 present a major challenge to health-care systems around the world.
T2DM is a complex endocrine and metabolic disorder in which the interaction between genetic and environmental factors generates a heterogeneous and progressive pathology with varying degrees of insulin resistance and dysfunction of pancreatic β cells and α cells, as well as other endocrine disturbances [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (FIG. 1) . Insulin resistance results from deficits in signalling pathways at the level of the insulin receptor and downstream, and T2DM emerges when β cells can no longer secrete sufficient insulin to overcome insulin resistance 4, [15] [16] [17] . Overweight and obesity are major risk factors for the development of insulin resistance 4, 5, 16, [18] [19] [20] . Hyperglycaemia is the fundamental biochemical feature of T2DM, causing oxidative and nitrosative stress and activation of inflammatory pathways and endothelial dysfunction, as well as precipitating microvascular complications and contributing to macrovascular disease, which are major causes of morbidity and mortality 21 . The results of several randomized controlled trials (RCTs) have demonstrated the short-term and long-term benefits of improving glycaemic control in delaying the onset and reducing the severity of diabetes-related outcomes, particularly retinopathy, nephropathy, neuropathy and cardiovascular disease, and also mortality [22] [23] [24] [25] . Attaining normal (or nearly normal) levels of blood glucose (where practical) is a major aim of T2DM treatment. Several strategies are available for this purpose: lifestyle changes, including dietary prudence, weight loss and physical activity, remain the cornerstones of management, but because of the progressive nature of T2DM and the difficulty in maintaining lifestyle changes in the long term, most patients also require oral therapies and (eventually) injectable treatments 26 . For more than four decades, only two classes of oral glucose-lowering medications were available (biguanides and sulfonylureas), but in the past 20 years many more . The long-term benefits of intensive glycaemic control on T2DM-related complications and mortality are well known, particularly when initiated promptly after diagnosis in young patients who do not yet have comorbid complications [22] [23] [24] [25] . However, intensive glycaemic control is not without risks, such as hypoglycaemia, weight gain and possible cardiovascular events and mortality in highrisk individuals. These risks might relate, at least in part, to the choice of glycaemic target and medications 22, [31] [32] [33] [34] [35] [36] , so an individualized management strategy is preferable 36 . The difficulty lies in the identification of patients in whom the risks associated with intensive glycaemic control outweigh the benefits. Stringent glycaemic control is not advised in elderly patients or in those with advanced disease, long T2DM duration or established cardiovascular disease 27, 36 . An HbA 1c target of 7% is commonly given in guidelines, but a lower target might be appropriate for newly diagnosed, young patients with T2DM and no complications, and a higher target might be more realistic for an elderly or frail patient with a long duration of disease and established complications.
Biguanides
The only biguanide available in clinical practice is metformin (dimethylbiguanide) 37 . Other biguanides (phenformin and buformin) have been withdrawn because of risks of lactic acidosis 38 . Biguanides were derived from the guanidine-rich herb Galega officinalis (French lilac), which was used in traditional medicine in Europe 37, 39 . Metformin was introduced into clinical practice in Europe in 1957 and in the USA in 1995, and has become the most prescribed agent for T2DM worldwide 37, 39 .
Mechanism of action
Metformin enters cells mainly via solute carrier family 22 member 1 (also known as organic cation transporter 1 (hOCT1)) and exerts multiple insulindependent and insulin-independent actions according to the level of drug exposure and the control of nutrient metabolism within different tissues 28, 37, [40] [41] [42] (FIG. 2) .
During treatment, the gut is exposed to high concentrations of metformin 42 , which interrupt the mitochondrial respiratory chain at complex I, and increase glucose utilization, anaerobic glycolysis and lactate production; some of the lactate can be converted back to glucose in the liver 43 . Lactate-glucose turn over causes energy dissipation, which might contribute to the weight neutrality (lack of weight gain or weight loss) observed in metformin-treated patients 28, 42 . In the liver, metformin increases insulin signalling, reduces glucagon action and reduces gluconeogenesis and glyco genolysis 28 . Metformin can inhibit the mitochondrial redox shuttle enzyme glycerol-3-phosphate dehydrogenase, altering the hepatocellular redox state and resulting in reductions in the ATP:AMP ratio, hepatic gluconeogenesis and the conversion of lactate and glycerol to glucose, and activation of AMP-activated protein kinase (AMPK) 44 . In addition, metformin treatment results in a shift toward the utilization of glucose relative to fatty acids as a cellular source of energy in the liver 37 . In muscle, metformin promotes insulinmediated glucose uptake via solute carrier family 2, facilitated glucose transporter member 4 (GLUT-4) 28 . As delayed-release formulations of metformin have achieved similar efficacies at lower doses compared with 'regular' formulations, it seems that the gut is a major site of metformin action at therapeutic doses 45 . Metformin can increase circulating levels of glucagon-like peptide-1 (GLP-1) from pretreatment levels, even in the absence of an oral glucose load and in individuals with and without T2DM [46] [47] [48] [49] [50] , by mechanisms that could include inhibition of sodium-dependent bile-acid transporters, which increase the availability of ileal bile acids to activate G-protein coupled bile acid receptor 1 (commonly known as TGR5) on enteroendocrine L cells. Compared with placebo, metformin reduces the activity of dipeptidyl peptidase 4 (DPP-4) 46 . Relative to pretreatment levels, metformin increases GLP-1 secretion in response to an oral glucose load, via muscarinic (M3) and gastrin-releasing peptide receptor (GRP-R)-dependent pathways [47] [48] [49] [50] [51] . In mice, metformin stimulates expression of GLP-1 receptor (Glp-1r) on pancreatic β cells, mediated by peroxisome proliferator-activated receptor
Key points
• Greater understanding of the complex and multifactorial pathogenesis of type 2 diabetes mellitus (T2DM) has informed the development of several new classes of glucose-lowering therapies • Metformin remains the first-line pharmacotherapy for patients with T2DM, whereas the use of other well-established agents, such as sulfonylureas, meglitinides, pioglitazone and α-glucosidase inhibitors, varies in different regions • Agents that enhance incretin activity (DPP-4 inhibitors), supplement endogenous GLP-1 (GLP-1 receptor agonists) or increase urinary glucose elimination (SGLT2 inhibitors) have low risk of hypoglycaemia and can assist weight control • Treatment with two or three agents with different modes of action can be required as T2DM advances, and insulin therapy is required if other agents are unable to maintain adequate glycaemic control • Glycaemic targets and the choice of glucose-lowering agents should be customized to meet the needs and circumstances of individual patients, which could be facilitated by future developments in pharmacogenomics • Although the balance of benefits and risks for different agents varies between individual patients, early, effective and sustained glycaemic control delays the onset and reduces the severity of hyperglycaemia-related complications (PPAR) α 49 . The effect of metformin on GLP-1 might contribute to its weight-neutral effect and to reduction in hepatic glucose output by inhibiting glucagon secretion [46] [47] [48] . Metformin also affects the circadian control of glucose metabolism in liver and muscle 42 . Metformininduced AMPK activation results in phosphorylation of casein kinase I, which leads to degradation of the circadian clock component mPer2, thereby increasing expression of the CLOCK and BMAL1 circadian genes and causing phase advance in the circadian rhythm in treated rodents, compared with untreated controls 52, 53 . The results of a study involving mice showed that metformin causes phase advance in the liver, but phase delay in muscle 53 , and the effects of metformin on circadian rhythm are blocked in mice with knock-out of Prkaa2, the gene encoding AMPK subunit α2 (REF. 52 ).
Pharmacokinetics
Metformin has an oral bioavailability of 40-60% and a plasma half-life of 4-9 h, and is eliminated unchanged in the urine mostly via tubular secretion rather than glomerular filtration 28, 54 .
Pharmacodynamics
Metformin is widely used as a first-line pharmacotherapy in patients with T2DM, because of its efficacy, long-term safety record, low risk of hypoglycaemia, weight neutrality and favourable effect on vascular disease 36 . Metformin treatment typically leads to a reduction in fasting plasma glucose (FPG) by 2-4 mmol/l and HbA 1c by 1-2%, largely independent of age, weight and T2DM duration as long as some residual β-cell function remains 28, 39 . In the 10-year follow-up data from the UK Prospective Diabetes Study (UKPDS), patients who received metformin had significant risk reductions for any diabetes-related end point of 21% (P = 0.01), diabetes-related death of 30% (P = 0.01) and myocardial infarction of 33% (P = 0.005) compared with overweight patients in the conventional therapy group 23, 28, 55 . Metformin might also be associated with a reduction in the risk of cancer in patients with T2DM, particularly prostate, pancreas and breast cancer 28, 42 . The progressive nature of T2DM can require the addition of other glucose-lowering treatments (including insulin) to metformin 15, 36, 56 . Many fixed-dose combinations of drugs that include metformin are, therefore, available. Multiple genetic and environmental factors give rise to type 2 diabetes mellitus (T2DM) through insulin resistance with pancreatic β-cell failure. Overweight and obesity contribute to insulin resistance in association with increased inflammatory signals and disturbed lipid homeostasis, often preceding the onset of hyperglycaemia by many years and enhancing cardiovascular risk. When insulin secretion is no longer sufficient to overcome insulin resistance, glucose intolerance progresses to T2DM, usually accompanied by pancreatic α-cell dysfunction that elevates glucagon secretion, reduced prandial secretion or activity of incretin hormones such as glucagon-like peptide 1 (GLP-1), alterations to the gut microbiome and disturbances of neural activities controlling hunger-satiety and the circadian regulation of glucose homeostasis. Insulin, sulfonylureas and meglitinides are associated with risk of hypoglycaemia. DPP-4, dipeptidyl peptidase 4; SGLT2, sodium/glucose cotransporter 2. 
Tissue-specific effects in T2DM
Factors that contribute to defective blood glucose control in T2DM 
Safety and adverse effects
The main adverse effects of metformin treatment are abdominal discomfort and other gastrointestinal effects, including diarrhoea 37 . Symptoms can diminish if the dose is reduced, but around 10% of patients cannot tolerate the drug at any dose 37 , possibly because of variants of hOCT1 that lead to an increased concentration of metformin in the intestine 57 . The risk of metformin intolerance (defined as patients who stop metformin within the first 6 months of treatment) is increased by concomitant use of drugs that inhibit hOCT1 activity (including tricyclic anti depressants, citalopram, proton-pump inhibitors, verapamil, diltiazem, doxazosin, spironolactone, clopidogrel, rosiglitazone, quinine, tramadol and codeine; OR 1.63, 95% CI 1.22-2.17, P = 0.001) or the presence of two alleles of SLC22A1 associated with reduced function of hOCT1 rather than one allele or no deficient allele (OR 2.41, 95% CI 1.48-3.93, P <0.001) 57 . Metformin is contraindicated in patients with advanced chronic kidney disease (CKD), notable liver disease or conditions that might predispose to hypoxia or reduced tissue perfusion. However, observational and database studies indicate that advantage can be taken of the broad therapeutic index with metformin 38, 58, 59 , and careful attention to dose has enabled its use even in patients with cardiovascular disease (including mild-to-moderate heart failure 38, 60 and chronic obstructive pulmonary disease 61 ). Adjusting the dose and monitoring renal function to ensure adequate elimination are important considerations, and metformin therapy should be stopped if hypoxaemia occurs 62, 63 .
Results of the UKPDS showed that, compared with sulfonylureas and insulin in patients with obesity and newly diagnosed T2DM, metformin use was associated with significantly reduced rates of myocardial infarction, stroke and all-cause mortality (by 39%, 41% and 36%, respectively) 64, 65 . The 10-year follow-up of the UKPDS showed that the reductions in myocardial infarction and mortality persist 23 . Database analyses have consistently provided corroborating evidence for this effect 65 . Increasing levels of use of statins and renal-protective medications make it difficult to assess the effect of metformin on cardiovascular disease 65 , although several RCTs are ongoing to assess this effect 65 .
Sulfonylureas
Sulfonylureas were developed as variants of sulfonamides after the latter were reported to cause hypoglycaemia 37, 66 . Sulfonylureas are classified as first-generation (such as tolbutamide and chlorpropamide) and second-generation (such as glibenclamide (glyburide), gliclazide, glipizide and glimepiride) 37 ; the second-generation drugs have greater potency, enabling treatment with lower doses.
Mechanism of action
Sulfonylureas act directly on pancreatic β cells by binding to the cytosolic face of ATP-binding cassette sub-family C member 8 (also known as sulfonylurea receptor 1 (SUR1)), which is part of the K ir 6.2 ATP-sensitive potassium channel 37, 67 . Binding closes the K ir 6.2 channel, preventing potassium efflux and depolarizing the plasma membrane. 
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Cost is based on lowest-priced member of the class. AMPK, 5ʹ AMP-activated protein kinase; BD, twice-daily; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; GLP-1RA, GLP-1 receptor agonist; OD, once daily; PPAR-γ, peroxisome proliferator-activated receptor γ; QDS, four times daily; QW, once weekly; RCT, randomized controlled trial; SGLT2, sodium/glucose cotransporter 2; SMBG, self-monitoring of blood glucose; SUR1, sulfonylurea receptor 1; TDS, thrice daily.
This opens local voltage-dependent calcium channels, increasing the influx of calcium and activating calcium-dependent signalling proteins, leading to insulin exocytosis (FIG. 3) . In vitro studies show that persistent exposure to sulfonylureas for several days can desensitize β cells and reduce the insulin-secretory response. However, studies in patients with T2DM have shown that a 25% increase in 24-h insulin secretion with the sulfonylurea glibenclamide is maintained for 6-10 weeks, although efficacy usually declines after 6-12 months of sulfonylurea therapy during clinical trials 68 .
Pharmacokinetics
Sulfonylureas vary considerably in their pharmacokinetic properties 37, [68] [69] [70] (see Supplementary information S1 (table)). They have high bioavailability and reach peak plasma concentrations within 1.5-4.0 h 68 . They are metabolized in the liver to varying extents to form a number of active and inactive metabolites that are eliminated along with unchanged drug via the bile and urine; caution is needed when treating patients with hepatic and/or renal impairment 37 . Half-lives are <10 h for some sulfonylureas, but extend to >24 h for others. Therapeutic effects are exerted for much longer than is indicated by the half-life if active metabolites are formed (as they are with glimepiride, glibenclamide and chlorpropamide) 68 .
In general, first-generation sulfonylureas should be avoided in patients with CKD stages 3 or 4 or those who are undergoing dialysis, in whom gliclazide and glipizide are suitable without extensive dose adjustment [71] [72] [73] . Glimepiride is an option for patients with CKD but not receiving dialysis, on the proviso of low-dose initiation and careful titration 71, 73 . More than 90% of sulfonylureas in the circulation are bound to plasma proteins, which can lead to interactions with other protein-bound drugs such as salicylates, sulfonamides and warfarin 37, 68 . Some medications potentiate the glucose-lowering effects of sulfonylureas by inhibition of their hepatic metabolism (for example, some antifungals and monoamine oxidase inhibitors), displacing them from binding to plasma proteins (for example, coumarins, NSAIDs and sulfonamides), The intestine is exposed to high levels of metformin, which have insulin-independent effects, whereas liver and muscle are exposed to lower concentrations of metformin that influence the metabolic effects of insulin. Metformin can improve insulin sensitivity via effects on insulin-receptor signalling and post-receptor signalling pathways of insulin action. Metformin can alter cellular nutrient metabolism and energy production independently of insulin via suppression of the mitochondrial respiratory chain and activation of 5ʹ AMP-activated protein kinase (AMPK). ACC, acetyl-CoA carboxylase; FBPase, fructose-1,6-bisphosphatase; G6Pase, glucose-6-phosphatase; GLUT, glucose transporter isoform; hOCT1, organic cation transporter 1; IRS, insulin receptor substrate; LKB1, serine/threonine-protein kinase STK11; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PDK, 3-phosphoinositide-dependent protein kinase; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol-3,4-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PKB, protein kinase B; GPD-M, glycerol-3-phosphate dehydrogenase, mitochondrial. inhibiting their excretion (for example, probenecid) or antagonizing their mechanism of action (for example, diazoxide and other K ATP -channel openers) 37 . Drugs such as rifampicin that induce sulfonylurea metabolism inhibit glucose-lowering by sulfonylureas 37 . Altered sulfonylurea formulations can enable rapid onset of action (as is the case with micronized glibenclamide) or prolonged activity (for example, 'Glipizide Extended Release' and 'Gliclazide Modified Release') while maintaining glucose-lowering efficacy 37, [74] [75] [76] .
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Pharmacodynamics
As monotherapy, sulfonylureas can lead to reductions in FPG by 2-4 mmol/l and HbA 1c by 1-2% 28, 37, 68, 70 . However, the failure rates of sulfonylureas as monotherapy are greater than those of metformin or rosiglitazone 15 . Sulfonylureas can be used as first-line treatment options in patients who are intolerant of metformin, and can be used in combination with most other glucose-lowering medications, except meglitinides, which have a similar mechanism of action 28, 37 . The size and durability of the response to sulfonylureas is positively associated with the reserve of β-cell function 37 .
Safety and adverse effects
Hypoglycaemia and weight gain are the main adverse effects associated with sulfonylureas. Weight gain of 1-4 kg that stabilizes after about 6 months is common following drug initiation 28 . Weight gain is probably related to the anabolic effect of the increased insulin levels and reduction of glycosuria 27, 28, 56 . Hypoglycaemia has been reported in 20-40% of patients receiving sulfonylureas, and severe hypoglycaemia (requiring third-party assistance) occurs in 1-7% of patients 28, 37, 77 , depending on the population, the definition of hypoglycaemia and the type and pharmacokinetics of the sulfonylurea 74 . In a study involving six UK secondary care centres, self-reported hypoglycaemia prevalence was 39% (95% CI 30-49%), similar to that in patients with T2DM treated with insulin for <2 years 77 . The prevalence of self-reported severe hypoglycaemia was 7% (95% CI 3-13%) 77 . Continuous glucose monitoring (CGM) showed that 22% (95% CI 15-31%) of patients had at least one episode of interstitial glucose <2.2 mmol/l, similar to patients with T2DM treated with insulin for <2 years 77 . These results confirmed that the use of long-acting sulfonylureas with active metabolites is especially associated with hypoglycaemia 28, 37 , and that the elderly, those living alone and those with renal or liver impairment, as well as car drivers, require extreme caution during treatment with sulfonylureas, as do those prescribing these drugs 28, 37 . Education and glucose self-monitoring are essential in patients receiving sulfonylureas; the results of an RCT 78 involving patients receiving Gliclazide Modified Release showed that self-monitoring of blood glucose reduced both the risk of symptomatic hypoglycaemia and the reduction in HbA 1c , compared with no monitoring.
The cardiovascular safety of sulfonylureas is controversial. In the 1970s, the University Group Diabetes Program raised concerns regarding increased cardiovascular disease risk with tolbutamide 79 , and since then many database studies, mostly retrospective, have suggested that sulfonylureas (particularly glibenclamide) are associated with less benefit than metformin against cardiovascular disease in patients with T2DM 65 . However, the results of RCTs such as UKPDS, ADVANCE and ACCORD did not show an increase in cardiovascular mortality or morbidity in sulfonylurea-treated patients 65 .
The ongoing CAROLINA study 80 comparing linaglitpin with glimepiride in patients with T2DM might help to define the cardiovascular safety of these drugs.
Meglitinides
The two main meglitinides (or glinides) are nateglinide and repaglinide. The class takes its name from the meglitinide moiety of glibenclamide, which exerts an insulin-releasing effect independently of the sulfonyl moiety 26, 28, 81 .
Mechanism of action
Meglitinides bind to the benzamido site of SUR1 on β cells. This site is separate from the sulfonyl-binding site, but meglitinide binding has a similar effect to sulfonylurea binding on the K ir 6.2 channels 37 (FIG. 3) . However, the relatively rapid onset and short duration of action of meglitinides suits their use as prandial glucose-lowering agents 37 .
Pharmacokinetics
Repaglinide is almost completely absorbed, with peak plasma concentrations after about 1 h. Repaglinide binds to proteins in the circulation, and is rapidly metabolized in the liver (mostly by cytochrome P450 3A4 (CYP3A4)), producing inactive metabolites that are mostly excreted in the bile. A plasma half-life of around 1 h 37,82,83 makes it suitable for patients with poor renal function. Taken approximately 15 min before a meal, repaglinide produces a prompt insulin response that lasts 4-6 h 37 . Bioavailability is unaffected by the ingestion of food. Repaglinide concentrations are positively affected by co-treatment with drugs that inhibit CYP3A4 (such as ketoconazole, antibacterial agents, steroids and cyclosporine), and negatively affected by drugs that induce CYP3A4 (such as rifampicin, carbamazepine and barbiturates) 83, 84 . Nateglinide has a slightly faster onset and shorter duration of action (3-5 h) than repaglinide, but is also protein-bound in the circulation and metabolized in the liver by CYP3A4, producing metabolites that are mostly excreted in the urine 37, 83 . Pharmacodynamics Repaglinide (0.5-4.0 mg) or nateglinide (60-180 mg) taken before meals produces dose-dependent increases in insulin concentrations and reduces postprandial and fasting hyperglycaemia 37 . Meglitinides are well-suited to patients with irregular meal patterns, or to elderly patients at high risk of hypoglycaemia 37 . Meglitinides are usually used in combination with metformin, a thiazolidinedione or insulin, although they can be used as monotherapy. The results of RCTs have shown that HbA 1c reductions are similar to, or slightly less than, those observed with sulfonylurea treatment when meglitinides are used as monotherapy or as an add-on to metformin 37, 83 . Repaglinide can be used effectively in conjunction with basal and biphasic insulins 85, 86 . In an RCT 86 with treatment for 12 months, nonobese patients with long-term T2DM (n = 102) were randomly assigned to receive either repaglinide or metformin, both in combination with biphasic insulin aspart 30/70 (30% soluble insulin aspart and 70% intermediate-acting insulin aspart), which was titrated to achieve an HbA 1c level of <6.5%. At the end of treatment, HbA 1c reductions were similar in both treatment groups (baseline versus studyend HbA 1c 8.15 ± 1.32 versus 6.72 ± 0.66% with metformin and 8.07 ± 1.49% versus 6.90 ± 0.68% with repaglinide, P = 0.2 for between-groups difference) 86 .
In a head-to-head RCT 87 in which 150 drug-naive patients were randomly assigned to receive either repaglinide (0.5 mg per meal, maximum dose 4 mg per meal) or nateglinide (60 mg per meal, maximum dose 120 mg per meal) for 16 weeks, HbA 1c reductions from an average of 8.9% at baseline were greater with repaglinide than nateglinide (−1.57% versus −1.04%, P = 0.002). Reductions in FPG were also greater with repaglinide than nateglinide (−57 mg/dl versus −18 mg/dl, P <0.001) 87 .
Safety and adverse effects
Results of studies with repaglinide and nateglinide have shown variable rates of hypoglycaemia, and generally less weight gain than with sulfonylureas 83, [88] [89] [90] [91] [92] . In a head-to-head RCT 87 , hypoglycaemia (blood glucose <50 mg/dl) was more commonly associated with treatment with repaglinide than with nateglinide (7% versus 0%). Weight gain was also slightly greater in the repaglinide group (1.8 kg versus 0.7 kg) 87 . As co-treatments with biphasic insulin, repaglinide and metformin resulted in similar rates of hypoglycaemia, but weight gain was less with metformin (difference in mean body weight = −2.51 kg, 95% CI −4.07 kg to −0.95 kg) 86 . Figure 3 | Sulfonylureas, meglitinides and glucagon-like peptide 1 receptor agonists (GLP-1RAs) act on pancreatic β cells to increase nutrient-induced insulin secretion. These agents bind to the cytosolic surface of the sulfonylurea receptor 1 (SUR1), which is part of the ATP-sensitive K ir 6.2 potassium channel. Binding of the sulfonylurea or meglitinide closes the K ir 6.2 channel, preventing potassium efflux and thereby depolarizing the plasma membrane. Depolarization opens local voltage-dependent calcium channels, increasing the influx of calcium and activating calcium-dependent signalling proteins that control insulin exocytosis. GLP-1RAs enhance nutrient-induced insulin release mainly via a cAMP-EPAC2-mediated potentiation of granule exocytosis. DAG, diacylglycerol; EPAC2, rap guanine nucleotide exchange factor 4; GLUT, glucose transporter isoform; IP3, inositol-1,4,5-trisphosphate; Rap1, Ras-related protein 1; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C. Nature Reviews | Endocrinology Meglitinides can bind to the sulfonylurea receptor 2 splice variants SUR2A and SUR2B, which are expressed by cardiovascular tissues 83, 93 . In the large NAVIGATOR RCT 94 , nateglinide did not alter cardiovascular outcomes in people with impaired glucose tolerance who either had, or were at high risk of, cardiovascular disease. No association has been demonstrated between repaglinide and either cardiovascular disease or cardiovascular risk 65, 83, 95 .
α-Glucosidase inhibitors (AGIs)
Acarbose was the first AGI to be introduced, in the early 1990s; subsequently, miglitol and voglibose were introduced in some countries. AGIs are widely used in Asian populations that have diets in which complex carbohydrates predominate 37 .
Mechanism of action
AGIs competitively inhibit α-glucosidase enzymes in the brush border of enterocytes lining the intestinal villi, preventing the enzymes from cleaving disaccharides and oligosaccharides into monosaccharides 37, 96 . This action delays carbohydrate digestion and defers absorption distally along the intestinal tract, reducing blood-glucose excursions and lowering prandial insulin levels 37 . Compared with controls, AGI treatment can also increase postprandial GLP-1 secretion and reduce secretion of glucose-dependent insulinotropic polypeptide (GIP) 97, 98 . The affinities of AGIs vary for different α-glucosidase enzymes, resulting in specific activity profiles (for example, acarbose has greater affinity for glycoamylase than for other glucosidases, whereas miglitol is a stronger inhibitor of sucrase) 37 .
Pharmacokinetics
Acarbose is degraded by amylases and bacteria in the small intestine; <2% of the unchanged drug is absorbed (along with some of the intestinal degradation products). Absorbed material is mostly eliminated in the urine within 24 h 37 . Miglitol is almost completely absorbed, and is eliminated unchanged in the urine 37 .
Pharmacodynamics
Typical HbA 1c reductions with AGI treatment are ~0.5%, mostly through reductions in postprandial glycaemia; reductions depend upon the amount of complex carbohydrate in the diet 28 . In a noninferiority RCT 99 of Chinese patients (n = 784) with newly diagnosed T2DM and mean HbA 1c of 7.5%, acarbose resulted in HbA 1c reductions similar to those with metformin (−1.1%, within groups difference 0.01%, 95% CI −0.12% to 0.14%). However, the sulfonylurea tolbutamide resulted in greater HbA 1c reductions compared with acarbose (−1.8% versus −1.1%; mean difference 0.6%, 95% CI 0.2-1.0%) in newly diagnosed drug-naive patients with T2DM (n = 96, mean baseline HbA 1c ~8%) 100 . Tolbutamide had a greater effect on FPG than acarbose, whereas their effects on postprandial glucose were similar 100 .
Safety and adverse effects
Gastrointestinal adverse effects of AGIs (flatulence, abdominal discomfort and diarrhoea) are commonly encountered and can lead to treatment withdrawal. Hypoglycaemia is uncommon. AGIs do not cause weight gain, and they have no clinically significant drug interactions.
The results of the STOP-NIDDM RCT showed that acarbose reduces the risk of developing T2DM, delays the onset of hypertension and reduces macrovascular events by 49% compared with placebo, but the total number of events was too small (n = 47) to draw firm conclusions 65, 101, 102 . A large RCT 103 assessing the impact of acarbose on cardiovascular outcomes is ongoing.
Thiazolidinediones
Drugs derived from thiazolidinedione include pioglitazone, rosiglitazone and troglitazone. Troglitazone was introduced in 1997 and withdrawn soon after because of hepatotoxicity 28 . Rosiglitazone and pioglitazone were introduced in 1999. Rosiglitazone was discontinued in Europe and its use was restricted in the USA in 2008 after reports of an association with cardiovascular risk; the FDA lifted the restrictions in 2013. Pioglitazone was discontinued in 2011 in some European countries pending enquires into a possible risk of bladder cancer.
Mode of action
Thiazolidinediones are agonists of the peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor that is highly expressed in adipose tissue, and to a lesser extent in muscle, liver, β cells, vascular endothelium and macrophages 37, 104 . PPAR-γ activation alters gene expression, promoting adipogenesis, insulin sensitivity and tissue glucose uptake, reducing inflammation and altering energy balance 104, 105 in a tissuespecific manner. PPAR-γ activation reduces hepatic gluconeogenesis, modifies the blood lipid profile and possibly improves β-cell viability 104, 105 . Differentiation of pre-adipocytes into new small insulin-sensitive adipocytes by PPAR-γ activation reduces circulating levels of free fatty acids, which reduces ectopic lipid accumulation in skeletal muscle and liver and rebalances the Randle (glucose-fatty acid) cycle in favour of glucose utilization by restricting availability of free fatty acids as an energy source for hepatic gluconeogenesis 28 .
Pharmacokinetics
Thiazolidinediones reach peak plasma levels within 1-2 h 37 . In the circulation, thiazolidinediones are almost entirely bound to plasma proteins, but their concentrations are not sufficient to interfere with other proteinbound drugs 37 . Pioglitazone is metabolized by cytochrome P450 2C8 (CYP2C8) and CYP3A4 to weakly active metabolites that are eliminated via bile, whereas rosiglitazone is metabolized by CYP2C9 and CYP2C8 to inactive metabolites that are excreted via urine 37, 106 . Rifampicin induces expression of CYP3A4, resulting in a reduction in levels of rosiglitazone and pioglitazone, whereas the lipid-lowering fibrate gemfibrozil inhibits CYP2C8, leading to accumulation of rosiglitazone and pioglitazone 106 .
Pharmacodynamics
Maximal doses of thiazolidinediones can reduce HbA 1c by 0.7-1.6% when used as monotherapy or in combination with metformin, sulfonylureas or insulin 104, 107 . In an RCT 108 , patients with T2DM receiving metformin (n = 630, mean age ~56 years, mean diabetes duration ~5.5 years, baseline mean HbA 1c 8.5-8.7%) were randomly assigned to either pioglitazone or gliclazide as an add-on treatment. After 2 years, the changes in HbA 1c were similar in the two arms (−0.89% with pioglitazone and −0.77% with gliclazide, P = 0.2 for between-groups difference), whereas pioglitazone resulted in greater reductions in FPG (−1.8 mmol/l versus −1.1 mmol/l, P <0.001) 108 . In another RCT 108 , patients with T2DM receiving a sulfonylurea (n = 639, mean age ~60 years, mean T2DM duration ~7 years, baseline mean HbA 1c 8.8%) were randomly assigned to either pioglitazone or metformin as an add-on treatment. After 2 years, the changes in HbA 1c were similar in the two arms (−1.03% with pioglitazone versus −1.16% with gliclazide, P = 0.17 for between-groups difference); reductions in FPG (around ~2 mmol/l) were also similar in the two arms 108 . Onset of the glucose-lowering effect of thiazolidinediones is gradual, taking 2-3 months to reach maximum effect 37 . The ADOPT trial 15 , in which 4,360 patients with T2DM (mean age 56-58 years, baseline HbA 1c 7.4%, mostly <2 years T2DM duration) were randomly assigned to glyburide, metformin or rosiglitazone, showed that rosiglitazone as monotherapy has a more prolonged effect on glycaemic control (measured by HbA 1c and FPG) than metformin or glyburide over 5 years. The glucose-lowering efficacy of thiazolidinediones is generally gradual in onset over several weeks, varies considerably between individuals, and no definite predictors are known to identify responders versus nonresponders 29 .
Safety and adverse effects
Thiazolidinediones do not affect the risk of hypoglycaemia when used as monotherapy or in combination with metformin. Oedema (often identified by rapid weight gain) has been reported in 4-6% of patients receiving thiazolidinediones 104 ; the observed fluid retention is the result of renal sodium reabsorption mediated by increased expression of sodium channel proteins in collecting duct epithelium 28 . Thiazolidinediones are associated with weight gain of 2-3 kg for each 1% drop in HbA 1c , whether used as monotherapy or in combination with metformin or insulin 104 . The weight gain is usually in subcutaneous adipose tissue, whereas visceral fat is either reduced or unaltered 104, 109 . In the ADOPT trial 15 , the weight gain with rosiglitazone over 5 years was greater than with glibenclamide (glyburide; treatment difference 2.5 kg, 95% CI 2.0-3.1 kg, P <0.001), whereas no difference was observed in waist circumference (treatment difference 0.77 cm, 95% CI −0.21 cm to 1.76 cm, P = 0.12).
The results of RCTs and observational studies show that, compared with control groups, long-term treatment with thiazolidinediones lowers bone density and doubles the risk of fractures in patients with T2DM, particularly in women 110 . In the ACCORD trial 111 , women who received a thiazolidinedione had double the risk of nonspinal fracture compared with those not using a thiazolidinedione; this risk was reduced after discontinuation of the thiazolidinedione. A meta-analysis of RCTs showed that, compared with metformin, sulfonylureas or placebo, thiazolidinediones reduce bone mineral density at the lumbar spine (difference −1.1%, 95% CI −1.6% to −0.7%, P <0.0001), total hip (−1.0%, 95% CI −1.4% to −0.6%, P <0.0001), forearm (−0.9%, 95% CI −1.6% to −0.3%, P = 0.007) and femoral neck (−0.7%, 95% CI −1.4% to 0.0%, P = 0.06), effects that were not reversed after 1 year of stopping treatment in some studies 112 . The cardiovascular safety of thiazolidinediones was questioned in a controversial meta-analysis that showed increased adverse cardiovascular outcomes in patients treated with rosiglitazone compared with controls without rosiglitazone, prompting withdrawal of rosiglitazone in Europe and restricted use in the USA 65, 113 . However, when the FDA re-examined the data from the RECORD study, no significant effect on cardiovascular risk was found 65, 114 . Pioglitazone is a ligand for PPAR-α (as well as PPAR-γ), and through PPAR-α it mitigates cardiovascular risk by positive effects on plasma levels of HDL cholesterol, reductions in plasma triglycerides and small dense LDL cholesterol particles, with the production of larger, more buoyant particles 115 . Thiazolidinediones can also have beneficial effects on blood pressure and endothelial function 65 , but compared with pioglitazone, rosiglitazone increases levels of plasma LDL cholesterol and triglycerides 65 .
In the PROACTIVE trial 32 , compared with placebo, pioglitazone was associated with a numerical but nonsignificant reduction in the composite outcome of all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries and amputation above the ankle (HR 0.90, 95% CI 0.80-1.02, P = 0.095). However, pioglitazone significantly lowered the occurrence of the secondary end point, a composite of all-cause mortality, nonfatal myocardial infarction and stroke (HR 0.84, 95% CI 0.72-0.98, P = 0.027) 32 . In addition, pioglitazone reduced the risks of subsequent myocardial infarction and recurrent stroke by 16% and 47%, respectively 65, 116, 117 . Nonetheless, the risk of heart failure was higher in the pioglitazone group than the placebo group in the PROACTIVE trial, although this risk was not associated with increased mortality 65 . However, both rosiglitazone and pioglitazone can cause congestive heart failure in patients who already have diastolic dysfunction, because of the propensity for oedema 65 . The effects of rosiglitazone on coronary artery disease are not clear, but pioglitazone might be beneficial 65, [118] [119] [120] [121] [122] .
DPP-4 inhibitors
The currently available DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) 123 are licensed as monotherapy, dual therapy, triple therapy and in combination with insulin, but there are some minor variations in licensing between agents. In addition, once-weekly DPP-4 inhibitors (omarigliptin and trelagliptin) are licensed in Japan 124, 125 .
Mechanism of action
The action of DPP-4 inhibitors causes elevation of circulating levels of incretin hormones, notably GLP-1 and GIP. The incretin effect is the ability of intestinal factors to enhance nutrient-induced insulin responses during feeding by 50-70% in healthy individuals 126, 127 ; this effect is much diminished in T2DM. GIP is secreted by K cells in the duodenum and jejunum in response to ingestion of carbohydrates and lipids [128] [129] [130] . In addition to its incretin effect, GIP reduces gastric acid secretion and has roles in adipogenesis and possibly β-cell proliferation 128, [130] [131] [132] [133] . GLP-1 is secreted by L cells mainly in the distal ileum and colon 128, 130 , and accounts for most of the incretin effect 128, 134 , including insulin biosynthesis 135, 136 . Additionally, GLP-1 causes a reduction in glucagon secretion, and has extrapancreatic actions that enhance satiety and delay gastric emptying (see Supplementary information S2 (box)) 127, 134, [137] [138] [139] . GIP and GLP-1 are rapidly degraded by DPP-4 (REF. 128 ), which acts on peptides to cleave N-terminal dipeptides with alanine (as in the incretins) or proline at position N2 (REF. 130 ). DPP-4 exists free in the circulation and also attached to endothelial cells 130, 140 , and is widely expressed in human tissues, including the intestine and portal system 130 . GLP-1 and GIP are generally inactivated almost immediately following secretion, and have half-lives of <2 min and 5-7 min, respectively 128, 130, 141, 142 . Compared with placebo treatment, DPP-4 inhibition results in a 2-3-fold increase in postprandial active GLP-1 levels 143, 144 . Unlike GLP-1 receptor agonists (GLP-1RAs), which can have an effect equivalent to a >10-fold increase in GLP-1, DPP-4 inhibitors do not delay gastric emptying or increase satiety and weight loss, but they do avoid initial nausea and vomiting 145, 146 .
Pharmacokinetics
Currently available DPP-4 inhibitors can produce 77-99% inhibition of DPP-4 activity and are appropriate for once-daily dosing, except for vildagliptin (twicedaily), and omarigliptin and trelagliptin (once-weekly). They are predominantly excreted in the urine, except for linagliptin, which does not require dose adjustment in patients with CKD (see Supplementary information S3 (table)) 123, [147] [148] [149] [150] [151] . DPP-4 inhibitors have little or no interaction with other glucose-lowering agents or drugs commonly used in patients with T2DM 123, 152 , possibly because DPP-4 inhibitors are neither inducers nor inhibitors of cytochrome P450 isoforms, and are not appreciably bound to plasma proteins 152 . However, saxagliptin is metabolized to an active metabolite by CYP3A4 and CYP3A5 (REFS 123, 152) .
Pharmacodynamics
On average, DPP-4 inhibitors reduce postprandial glucose excursions by ~3 mmol/l, and FPG by ~1.0-1.5 mmol/l 28, 123 . A meta-analysis 153 that assessed the efficacy of DPP-4 inhibitors as monotherapy or as add-on therapy to other oral agents included placebo-controlled or activecontrolled RCTs of DPP-4 inhibitors (n = 98 trials, 24,163 patients) of 12-54 weeks duration, with ≥30 patients in each treatment arm. The mean ages of the participants in all but two of these studies were 50-62 years; 88 of the 98 trials included were double-blinded and 10 were openlabel design 153 . The results showed that DPP-4 inhibitors reduce HbA 1c by −0.77% (95% CI −0.82% to −0.72%) from an average baseline of 8.05% 153 . In 18 RCTs with a duration of 52-54 weeks, DPP-4 inhibitors resulted in HbA 1c reductions of −0.84% (95% CI −0.99% to −0.68%, P <0.0001), whereas in 26 RCTs of 12-18 weeks duration, the HbA 1c reduction was −0.68% (95% CI −0.75% to −0.61%, P <0.0001) 153 .The HbA 1c reductions were largely similar across the class, but results from direct head-to-head trials are limited. In this meta-analysis, the HbA 1c reductions according to DPP-4 inhibitor were: vildagliptin 50 mg (n = 26, age 56.3 years, baseline HbA 1c 8.06%) −0.88% (95% CI −1.00% to −0.75%, P <0.0001); sitagliptin 100 mg (n = 37, age 55. A meta-analysis of 27 reports of 19 studies, including 7,136 patients, showed that DPP-4 inhibitor monotherapy was associated with a smaller decline in HbA 1c than metformin monotherapy (weighted mean difference (WMD) 0.20%, 95% CI 0.08-0.32%, P overall effect = 0.001). DPP-4 inhibitors combined with metformin produced smaller declines than GLP-1RAs combined with metformin (WMD 0.49%, 95% CI 0.31-0.67%, P overall effect <0.001) and sulfonylureas combined with metformin (WMD 0.07%, 95% CI 0.03-0.11%, P overall effect <0.001), but similar declines to pioglitazone combined with metformin (WMD 0.09%, 95% CI −0.07% to 0.24%, P overall effect = 0.28) 154 . In the studies comparing monotherapies, trial durations were 24-206 weeks, and participants had mean T2DM duration of 1.0-4.4 years and mean HbA 1c of 7.2-9.6%. In the trials of combination therapies, mean T2DM duration was 5.0-7.3 years and mean HbA 1c was 7.3-8.5% 154 .
The comparison of the efficacy of DPP-4 inhibitors with sulfonylureas is complicated by multiple factors including study duration, renal function and the choice of sulfonylurea for the active comparator 155 . In a meta-analysis 155 of 12 RCTs of ≥18 weeks duration that compared sulfonylureas head-to-head with DPP-4 inhibitors, the mean changes from baseline in HbA 1c were modestly but significantly smaller with DPP-4 inhibitors than with sulfonylureas (difference of mean changes in HbA 1c 0.105, 95% CI 0.103-0.107, P <0.0001). However, several RCTs of 1-3 years duration showed similar HbA 1c reductions for DPP-4 inhibitors and sulfonylureas 150, [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] . The glucose-lowering efficacy of DPP-4 inhibitors is greater in Asian patients with T2DM than in other ethnic groups (between-group HbA 1c difference −0.26%, 95% CI −0.36% to−0.17%, P <0.001), and might be affected by genetic factors such as a TCF7L2 gene variant 165, 166 . A meta-analysis of RCTs of ≥76 weeks duration suggested that the effect of DPP-4 inhibitors is not durable and lessens during the second year of treatment 167 .
Head-to-head comparisons of DPP-4 inhibitors
The number of head-to-head trials comparing DPP-4 inhibitors is limited. The results of an RCT 168 comparing saxagliptin and sitagliptin as add-on treatment to metformin in 810 patients (age 58.4 years, diabetes duration 6.3 years, baseline HbA 1c 7.7%) showed that HbA 1c reductions over 18 weeks are similar with both treatments (adjusted mean changes in HbA 1c −0.52 and −0.62%, respectively; between-group difference 0.09%, 95% CI −0.01% to 0.20%). However, sitagliptin resulted in a slightly greater reduction in FPG (−0.60 mmol/l for saxagliptin versus −0.90 mmol/l for sitagliptin; treatment difference 0.30 mmol/l, 95% CI 0.08-0.53 mmol/l) 168 . In another RCT 169 , 148 patients with T2DM and estimated glomerular filtration rate (eGFR) <30 ml/ min/1.73m 2 , who were either drug-naive or treated with any glucose-lowering agents were randomly allocated to vildagliptin 50 mg or sitagliptin 25 mg once daily. The treatments resulted in similar reductions in HbA 1c over 24 weeks (adjusted mean change in HbA 1c −0.54% from a baseline of 7.52% with vildagliptin versus −0.56% from a baseline of 7.80% with sitagliptin, P = 0.874). Vildagliptin lowered FPG by 0.47 ± 0.37 mmol/l, whereas FPG increased in the sitagliptin group by 0.16 ± 0.43 mmol/l, but the difference between groups was not significant (P = 0.185) 169 . In a phase III, noninferiority RCT 170 , 243 patients with T2DM that was inadequately controlled by diet and exercise were randomly assigned to receive trelagliptin (100 mg once weekly), alogliptin (25 mg daily) or placebo for 24 weeks. Trelagliptin was noninferior to alogliptin and resulted in similar reductions in HbA 1c (−0.33% versus −0.45%, respectively; least-squares mean difference (LSMD) 0.11%, 95% CI −0.054% to 0.281%). Both trelagliptin and alogliptin significantly reduced mean HbA 1c compared with placebo (P <0.0001) 170 . In another RCT 171 , 412 patients with T2DM, who were drug-naive or on oral glucose-lowering treatments, were randomly assigned to receive omarigliptin 25 mg weekly, sitagliptin 50 mg daily or placebo, for 24 weeks. At baseline, patients had mean HbA 1c of 7.9%, 8.0% and 8.1%, respectively, in the omarigliptin, sitagliptin and placebo groups 171 . Omarigliptin treatment resulted in HbA 1c reduction of −0.66% (95% CI −0.76% to −0.57%), which was significantly greater than with placebo (P <0.001) and similar to sitagliptin (LSMD −0.02%, 95% CI −0.15% to 0.12%), meeting the prespecified noninferiority criterion 171 .
Safety and adverse effects DPP-4 inhibitors are generally well tolerated, and the incidence of adverse effects is similar to placebo and lower than other glucose-lowering agents 154, 172 . The incidence of gastrointestinal symptoms is lower with DPP-4 inhibitors than with metformin or a GLP-1RA 154 . The risk of hypoglycaemia in patients treated with a DPP-4 inhibitor is very low except when combined with sulfonylureas or insulin 123, 154, 172 . DPP-4 has many substrates other than incretins, including bradykinin, encephalins, neuropeptide Y, peptide YY1-36, gastrin-releasing polypeptide, substance P, insulin-like growth factor 1, vasostatin 1, the α chains of thyrotropin, luteinizing hormone, chorionic gonado tropin and several chemokines, such as C-C motif chemokine 2 (monocyte chemotactic protein 1) 173 ; however, no adverse effects relating to these substrates have been observed in clinical trials 28, 123, 148 . In addition, DPP-4 is the T-cell activation antigen CD26, but no untoward immune-related effects have been demonstrated, either in Dpp4 knockout mice or with the use of DPP-4 inhibitors in animals or humans 28 . Several meta-analyses and pooled analyses have shown that DPP-4 inhibitors (individually and as a class) are associated with reductions in cardiovascular events 65, 174 . However, these studies were retrospective and not specifically designed to examine the effect of DPP-4 inhibitors on the incidence of cardiovascular disease 65 . The results of three RCTs (SAVOR-TIMI 175, 176 , EXAMINE 177 and TECOS 178 ) demonstrated that saxagliptin, alogliptin and sitagliptin are not associated with the risk of adverse cardiovascular outcomes 65, [175] [176] [177] [178] . The populations of patients in these trials were each slightly different. SAVOR-TIMI 175, 176 included patients with T2DM with either a history of, or a risk of, cardiovascular events. EXAMINE 177 included patients with T2DM and an acute myocardial infarction or hospitalization for unstable angina in the preceding 15-90 days. TECOS 178 included patients with T2DM who were >50 years old and had established cardiovascular disease.
These studies were designed to look specifically at the effects of DPP-4 inhibitors on cardiovascular safety so that patients in the placebo arms received other glucose-lowering therapies to minimize any differences in HbA 1c between arms. In the SAVOR-TIMI study 175, 176 , saxagliptin treatment was associated with a 3.5% incidence of hospitalization for heart failure, compared with 2.8% in the placebo arm (P = 0.007), with no increase in mortality, and this difference was independent of baseline renal function, although compared with placebo, saxagliptin reduced the development and progression of microalbuminuria 65, 175, 176 . No effect on heart failure was observed in the EXAMINE 177 or TECOS 178 trials, and the mechanism underlying the effect that was seen with saxagliptin is unclear. An ongoing study (CAROLINA 80 ) has been designed to examine the effect of linagliptin on cardiovascular outcomes with an active comparator (glimepiride) rather than placebo.
The individual results of the SAVOR-TIMI, EXAMINE and TECOS trials did not show any increased risk of pancreatitis or pancreatic cancer [175] [176] [177] [178] [179] , but a meta-analysis of these RCTs did demonstrate a significantly increased risk of acute pancreatitis in patients using DPP-4 inhibitors compared with those receiving standard care (OR 1.82, 95% CI 1.17-2.82, P = 0.008) 180 .
GLP-1RAs
Exenatide (twice daily) was the first GLP-1RA, and was introduced in 2005. Two once daily GLP-1RAs (liraglutide and lixisenatide) and three once weekly GLP-1RAs (exenatide, albiglutide and dulaglutide) are also now available for combination therapy with oral glucose-lowering agents and basal insulin (except exenatide once weekly, which is not licensed to be used with basal insulin). Dulaglutide and albiglutide are also licensed as monotherapy in patients who are intolerant to metformin.
Exenatide (synthetic exendin-4), a peptide originally isolated from saliva of the lizard Heloderma suspectum (Gila monster) 128, 181 , has 53% homology with human GLP-1 and contains an Ala8Gly substitution that confers resistance to degradation by DPP-4 (REFS 128,182). Exenatide once weekly sustained-release formulation consists of exenatide embedded within biodegradable polymeric microspheres of poly(DL-lactic-co-glycolic acid) 183 . Liraglutide is a true analogue of GLP-1 with the addition of a 16-carbon fatty acid chain attaching Lys26 to albumin, to mask the DPP-4 cleavage site 184 . Albiglutide has two copies of GLP-1 in series, each with an Ala8Gly substitution, and this molecule is fused to albumin 185 . Lixisenatide is an exendin-4 analogue with six Lys residues added at the C terminus to confer resistance to DPP-4 (REF. 186 ). Dulaglutide has two copies of a GLP-1 analogue (with amino acid substitutions Ala8Gly, Gly22Glu and Arg36Gly) covalently linked to an Fc fragment of human IgG4 (REF. 187 ). (FIG. 3) , contributing to reductions in fasting glycaemia and postprandial glycaemia, and to weight loss 188 (see  Supplementary information S2,S4,S5 (box, table, table) ). Therapeutic concentrations of GLP-1RAs are far higher than physiological levels of GLP-1, and although GLP-1 deficiency has been described in patients with T2DM, this deficiency is not a universal characteristic of the disease 188 . Pharmacokinetics GLP-1RAs are delivered by subcutaneous injection. Exenatide is rapidly absorbed 189 . T max is ~2 h, half-life is 3-4 h 189 and elimination is mostly renal by glomerular filtration and proteolytic degradation [190] [191] [192] (see  Supplementary information S6 (table) ). Relative to patients with normal renal function, exenatide clearance is decreased by 36% in patients with moderate renal disease (in whom it should be used with caution) and by 84% in those with severe renal disease (in whom it should not be used) 193 . The once weekly exenatide reaches therapeutic levels within 2 weeks and maximum concentrations by 6 weeks 194 . The half-life of liraglutide is 10-15 h, with a T max of 9-12 h [195] [196] [197] . Lixisenatide has a half-life of 2-4 h and a T max of 1-2 h 198 , and exerts its main effect on the meal immediately after injection. Albiglutide has a T max of 3-5 days and a half-life of 6-7 days 199 . Dulaglutide has a T max of 12-72 h, a half-life of ~4 days and reaches steady-state levels by 2 weeks 200 (see Supplementary information S6 (table) ). GLP-1RAs are not recommended in severe renal disease; they have limited drug interactions, but can affect the availability of other medicines, such as acetaminophen (paracetamol) and statins because of the delay in gastric emptying (except for exenatide once weekly, which has a minor effect on gastric emptying) 27, 201 .
Mechanism of action GLP-1RAs mimic GLP-1 and activate the GLP-1 receptor, potentiating nutrient-induced insulin secretion
Pharmacodynamics
The efficacy of GLP-1RAs has been explored in large programmes of placebo-controlled and active-comparator RCTs 
(see Supplementary information S4,S5 (tables)).
Effect on glycaemic measures. Exenatide (twice daily) significantly reduces measures of glycaemic control when used as monotherapy or add-on therapy (see Supplementary information S4 (table)) [239] [240] [241] [242] [243] . A meta-analysis 244 of RCTs in which exenatide was an add-on to existing metformin therapy for 16-30 weeks showed that exenatide lowers HbA 1c by 0.8% from an average baseline of 8.1 ± 0.6%. The effect of exenatide on HbA 1c reduction was greater in patients with baseline HbA 1c >9% than in those with HbA 1c ≤9% 239 , and was maintained at 3 years 240 and only deteriorated modestly through 6 years 245, 246 . Liraglutide improves glycaemic control when used as monotherapy or add-on therapy 239, 241, 247, 248 (see Supplementary information S4 (table)). Compared with glimepiride 8 mg daily, liraglutide 1.2-1.8 mg daily monotherapy resulted in greater reductions in HbA 1c from an average baseline of 8.3% (glimepiride −0.6%, liraglutide 1.2 mg −0.9% and liraglutide 1.8 mg −1.1%; treatment difference for liraglutide 1.2 mg −0.31%, 95% CI −0.54% to −0.08%, P = 0.008; treatment difference for liraglutide 1.8 mg −0.60%, 95% CI −0.83% to −0.38%, P <0.0001). A similar effect was seen for reductions in FPG (treatment difference for liraglutide 1.2 mg −0.63 mmol/l, 95% CI −1.17 mmol/l to −0.09 mmol/l, P = 0.02; treatment difference for liraglutide 1.8 mg −0.99 mmol/l, 95% CI −1.53 mmol/l to −0.45 mmol/l, P <0.001) and also postprandial glucose over 104 weeks 247 . In pooled patient data from seven phase III RCTs from the liraglutide development programme, with 26 weeks of liraglutide 1.8 mg, HbA 1c reductions were less in patients with baseline HbA 1c ≤7.5% than in those with HbA 1c >9.0% (−0.7% versus −1.8%) 249 . Lixisenatide significantly decreases HbA 1c and postprandial glucose when used as monotherapy or add-on therapy [210] [211] [212] [213] [214] [215] [250] [251] [252] [253] [254] [255] [256] [257] . In a meta-analysis of RCTs, compared with placebo, lixisenatide treatment produced reductions in 2 h postprandial glucose from baseline (LSMD −4.9 mmol/l, P <0.001), glucose excursion (LSMD −4.5 mmol/l, P <0.001) and postprandial glucagon (LSMD −19.0 ng/l, P <0.001) 256 . Compared with placebo, lixisenatide also reduced HbA 1c and postprandial glucose, but not FPG, when added to basal insulin 257 .
Exenatide once weekly reduces HbA 1c , FPG and postprandial glucose when used as monotherapy or add-on treatment 218, 239, 241, 258 . Exenatide once weekly monotherapy has been noninferior to metformin, superior to sitagliptin and similar to pioglitazone with regard to HbA 1c reduction in RCTs at 26 weeks 239, 258 . Addition of exenatide once weekly to metformin is more effective for the achievement of glucose control than addition of either sitagliptin or pioglitazone to metformin 218, 239 . In a study involving 456 patients with T2DM treated with metformin alone or with a sulfonylurea, addition of exenatide once weekly resulted in similar HbA 1c reductions to addition of insulin glargine; the effect of exenatide once weekly persisted at 3 years 222, 236, 239 . Similarly, addition of exenatide once weekly to oral glucose-lowering medication resulted in greater HbA 1c reductions over 26 weeks than addition of once daily or twice daily insulin detemir 239, 259 . In the extension phase of the DURATION-1 trial 260 , patients received exenatide once weekly for up to 5 years, and improvements in HbA 1c and FPG were maintained over this period. However, 40% of patients did not complete the study. Most of the loss of follow-up was because of withdrawal of consent, and only eight patients withdrew because of "loss of glucose control". No differences were identified in baseline characteristics between those who completed and did not complete the study, and HbA 1c reduction at 5 years was evident in the intention-to-treat analysis (−1.2% ± 0.1%) and the analysis of patients who completed the extension (−1.6% ± 0.1%).
Albiglutide has beneficial effects on glycaemic control when used as monotherapy or add-on therapy in phase III studies 250, 261, 262 . In an RCT lasting 104 weeks, treatments were added to metformin, and albiglutide provided significantly greater reductions in HbA 1c and FPG than placebo, sitagliptin or glimepiride 226 . As an add-on to treatment with metformin and sulfonylurea, albiglutide did not meet the prespecified noninferiority margin for the difference in the change of HbA 1c of 0.3% compared with pioglitazone over 52 weeks 223 . As an add-on to metformin (with or without sulfonylurea), albiglutide resulted in similar HbA 1c reductions to insulin glargine over 52 weeks 224 . As an add-on to insulin glargine, albiglutide was noninferior to insulin lispro at 26 weeks, but did not meet the noninferiority margin at 52 weeks 250, 263 . Dulaglutide 0.75 mg and 1.5 mg weekly treatments were more effective than metformin and sitagliptin when used as monotherapy or as add-on therapy to other oral glucose-lowering treatments over 52 weeks 232, 234, 250 . In addition to metformin and sulfonylureas over 52 weeks, compared with daily insulin glargine, dulaglutide 1.5 mg weekly was more effective and dulaglutide 0.75 mg was noninferior for the reduction of HbA 1c from baseline 237 .
A meta-analysis of RCTs of ≥12 weeks duration in which information about ethnicity was available showed that the WMD in HbA 1c for GLP-1RA treatment compared with placebo was −1.16% (95% CI −1.48% to −0.85%) in the pool of studies involving ≥50% Asian participants, and −0.83% (95% CI −0.97% to −0.70%) in the studies with <50% Asian participants (between-group difference −0.32%, 95% CI −0.64% to −0.01%, P = 0.04) 264 .
Effect on weight. GLP-1RAs are associated with reductions in body weight and waist circumference, but with much variation in individual responses and within-class differences 250, [265] [266] [267] [268] (see Supplementary information S5  (table) ). In a meta-analysis 266 of 15 RCTs, the combination of GLP-1RAs with basal insulin was shown to result in mean weight loss of −3.22 kg (95% CI −4.90 kg to −1.54 kg).
Effect on blood pressure. Results from individual RCTs and meta-analyses have shown that GLP-1RAs result in modest, but significant, reductions in systolic blood pressure, compared with placebo or insulin [269] [270] [271] (see Supplementary information S5 (table) ). This effect is independent of baseline blood pressure and the influence of the GLP-1RA on HbA 1c or body weight 269 . A reduction in diastolic blood pressure compared with placebo has also been observed with exenatide twice daily (−1.08 mmHg, 95% CI −1.78 mmHg to −0.33 mmHg) 270 .
Other effects. A meta-analysis has shown that GLP-1RAs modestly reduce levels of total cholesterol, LDL cholesterol and triglycerides, but do not improve HDL cholesterol levels, in comparison with placebo or active comparators 272 .
Safety and adverse effects
GLP-1RAs are generally well tolerated; the most common adverse effect is nausea, which is usually transient, resolving over 4-8 weeks, and which can be minimized by progressively increasing the dose 27, 28, 239, 250 . The risk of hypoglycaemia in patients receiving GLP-1RAs is low, unless they are combined with insulin or sulfonylureas 27, 28, 239, 250 . Injection-site reactions are common with some GLP-1RAs, including exenatide once weekly (≤17.6%) and albiglutide (≤22%) 250 . The occurrence of antibodies is also commonly associated with GLP-1RA treatment, but with little apparent clinical relevance, and generally with no influence on glycaemic control, except very occasionally in patients receiving exenatide once weekly who have high antibody titres 28, 194, 239, 250 . The possible association between GLP-1RAs and the risk of pancreatitis and pancreatic cancer has received much attention, but to date no definite causal link has been found 273 . Meta-analyses have shown no significant increase in acute pancreatitis with GLP-1RA treatment in patients with T2DM 179, 274, 275 . In addition, results from cardiovascular safety trials have not shown a significant increase in pancreatitis with GLP-1RAs 276 . The recommendation in the product labelling for GLP-1RAs to avoid therapy in patients with a history of pancreatitis and to discontinue treatment if pancreatitis develops is considered appropriate 28 . Thyroid C-cell hyperplasia and medullary cell carcinoma were also raised as possible concerns in preclinical studies in rodents, but clinical studies have not identified any substantial problems with GLP-1RA treatment 28, 239, 250 . The results of preclinical studies showed that GLP-1RAs have cardioprotective effects in heart failure and following myocardial ischaemia 65 . GLP-1RAs can have favourable effects on many cardiovascular risk factors, such as weight loss, blood pressure, endothelial function, inflammation, plasminogen activator inhibitor-1, postprandial lipaemia and LDL cholesterol 65 . Results of studies in patients with and without T2DM have shown a beneficial effect of GLP-1RAs on left ventricular function in patients with heart failure and on myocardial function and the myocardial salvage index following ischaemia 65, 277 . However, GLP-1RAs often stimulate the resting heart rate by ~3 bpm, most likely by activating GLP-1R in the sinoatrial node 65 . In an RCT 271 with 24-h ambulatory heart-rate monitoring, dulaglutide 1.5 mg was associated with increased heart rate compared with placebo (LSMD 2.8 bpm, 95% CI 1.5-4.2 bpm), unlike dulaglutide 0.75 mg and exenatide 271, 278 . Large RCTs assessing the cardiovascular safety of liraglutide, semaglutide, exenatide once weekly and dulaglutide are ongoing 65 . No adverse cardiovascular outcomes have been reported in patients with T2DM and established cardiovascular disease who were treated with lixisenatide 276 .
Head-to-head comparisons of GLP-1RAs
As several GLP-1RAs are available, with different chemical structures and formulations, the different pharmacokinetic and pharmacodynamic profiles seen in head-to-head trials could influence clinical decisionmaking 205, 216, [219] [220] [221] 227, 230, 231, 238, 279 (TABLE 2) . Overall, liraglutide 1.8 mg and dulaglutide 1.5 mg seem to have the greatest effects on HbA 1c , and liraglutide 1.8 mg and exenatide once weekly have the largest effect on weight reduction. Albiglutide has less effect on HbA 1c and weight reduction than other GLP-1RAs, but is associated with fewer gastrointestinal adverse effects. Once weekly preparations are associated more with injection-site reactions than once daily or twice daily agents.
In general, longer-acting GLP-1RAs produce greater reductions in FPG, but have less effect on postprandial glucose excursions, compared with shorter-acting GLP-1RAs 280, 281 . The effect on postprandial glucose is at least partly mediated by delayed gastric emptying, and occurs more with short-acting GLP-1RAs than with long-acting GLP-1RAs, which are subject to tachyphylaxis brought on by chronic elevation of plasma GLP-1 (REF. 280 ). In addition, lixisenatide, in contrast to liraglutide, strongly suppresses postprandial glucagon secretion 280 . Patient satisfaction is greater in those receiving exenatide once weekly or liraglutide, compared with exenatide twice daily 279 .
GLP-1RAs versus insulin
In a meta-analysis 282 of RCTs that compared GLP-1RAs with basal insulin progressively titrated to achieve FPG targets in patients with T2DM, GLP-1RAs resulted in greater reductions in HbA 1c (mean net change −0.14%, 95% CI −0.27% to −0.02%, P = 0.03) and weight (−4.40 kg, 95% CI −5.23 kg to −3.56 kg, P <0.01), but less reduction in FPG (1.18 mmol/l, 95% CI 0.43-1.93 mmol/l, P <0.01). GLP-1RAs were also associated with greater reductions in postprandial glucose compared with insulin 282 . Hypoglycaemia was reported to reduce in the GLP-1RA group (HR 0.45, 95% CI 0.27-0.76, P <0.01) 282 . In a separate RCT 283 , dulaglutide resulted in greater reduction in HbA 1c than insulin glargine, when added to insulin lispro.
Insulin-GLP-1RA combination
To simplify the co-administration of basal insulin and GLP-1RAs, these two agents have been combined into a single injection, a fixed-ratio combination (IDegLira), which was launched in the UK in 2014 (REF. 147 ). IDegLira combines 50 U of insulin degludec with 1.8 mg of liraglutide 147 ; the combination is titrated in the same way as insulin alone 147 . In a 26-week RCT 284 involving insulin-naive patients, HbA 1c decreased by 1.9% ± 1.1% with IDegLira, compared with 1.4% ± 1.0% with insulin degludec and 1.3% ± 1.1% with liraglutide. The IDegLira group had fewer reports of nausea than the liraglutide group and lower incidence of hypoglycaemia than the insulin degludec group 284 . These benefits were maintained at 52 weeks, with HbA 1c reductions of 1.84%, 1.40% and 1.21% for IDegLira, insulin degludec and liraglutide, respectively 285 . FPG was similar with IDegLira (5.7 mmol/l) and insulin degludec (6.0 mmol/l) by the end of the study, but higher with liraglutide (7.3 mmol/l) 285 . The improvements in glycaemic control were achieved with 37% less daily insulin dose with IDegLira than with insulin degludec 285 . IDegLira was associated with a significantly greater decrease in body weight (estimated treatment difference −2.80 kg, P <0.0001) and a 37% lower rate of hypoglycaemia compared with insulin degludec 285 . In patients who were already receiving basal insulin, HbA 1c decreased by 1.9% with IDegLira versus 0.9% with insulin degludec (treatment difference −1.1%, 95% CI −1.3% to −0.8%, P <0.0001). Mean weight reduction with IDegLira was 2.7 kg versus no weight change with insulin degludec, and the incidence of hypo glycaemia was similar (24% for IDegLira versus 25% for insulin degludec) 286 . Another fixed-ratio combination of lixisenatide and insulin glargine has completed phase III trials and a regulatory submission has been made to the FDA 287, 288 .
SGLT2 inhibitors SGLT2 inhibitors currently available in Europe and North
America are dapagliflozin, canagliflozin and empagliflozin. They can be used as monotherapy when diet and exercise are inadequate, and when metformin is not tolerated, and can also be used as add-on to other glucose-lowering agents, including insulin 289 . As their efficacy is dependent on the renal filtration of glucose, SGLT2 inhibitors should not be initiated in patients with eGFR <60 ml/min/1.73 m 2 , but in patients who are already receiving, and are tolerant of, canagliflozin or empagliflozin, these medications can be continued in patients with eGFR as low as 45 ml/min/1.73 m 2 (REF. 290 ).
Mechanism of action
SGLTs are secondary active membrane symporters that transfer sodium down its concentration gradient, usually into the cell, in conjunction with the transfer of specific hexose sugars or other molecules against their concentration gradient 291 . SGLTs in the intestine and kidneys transfer glucose across the luminal membrane into enterocytes or ductal epithelial cells; glucose transporters (GLUTs) mediate passive transfer of glucose across basolateral membranes down its concentration gradient 289, 292, 293 .
The main SGLTs are SGLT1 and SGLT2, which are primarily responsible for intestinal glucose absorption and for reabsorption of most of the filtered glucose in the kidney, respectively 291, 294 . SGLT2 is a low-affinity, high-capacity glucose transporter in the S1 segment of the proximal tubules, which is suited to reabsorption 1 receptor agonists (GLP-1RAs)   166,177,179,180,182,194,195,204,215,218-220,225,228 of a high concentration of filtered glucose entering the tubules. SGLT1, which is also expressed in the kidneys, is a high-affinity, low-capacity glucose transporter that is suited to reabsorption of glucose at low concentration in the S3 segment of the proximal tubules [294] [295] [296] . Competitively inhibiting SGLT2 can eliminate 60-90 g glucose per day 297 , but this amount can vary considerably depending on renal function and the degree of hyper glycaemia 289 . The effects of SGLT2 inhibition are self-limiting, as the efficacy decreases as hyperglycaemia lessens (and less glucose is filtered in the kidney). The effects of SGLT2 inhibition are insulin-independent, and efficacy is not affected by declining β-cell function or insulin resistance 28, 289 . However, insulin is still required, as SGLT2 inhibition does not treat the underlying endocrinopathies that contribute to the pathogenesis of T2DM, except by reducing the effects of glucotoxicity 28, 289 . SGLT2 inhibition and the associated glycosuria result in mild diuresis and calorie loss, leading to modest reductions in blood pressure and body weight 28, 289 . However, the weight loss associated with SGLT2 inhibitors is less than expected from the degree of glycosuria; patients typically have one-quarter to one-third of the weight loss predicted by their glycosuria. This effect is partly accounted for by an elevation of calorie intake, which correlates negatively with baseline BMI and positively with baseline eGFR 298 . In an RCT 299 that included 95 patients who were taking a GLP-1RA (which should counter increased calorie intake), addition of canagliflozin 300 mg resulted in significant weight loss compared with placebo (LSMD for change in weight −3.2%, 95% CI −4.5% to −2.0%) over 18 weeks.
Pharmacokinetics
The currently available SGLT2 inhibitors have half-lives of 10.6 h to 13.3 h 289,300-304 (see Supplementary information S7 (box)). Empagliflozin is the most specific. SGLT2 inhibition by dapagliflozin (10 mg per day), canagliflozin (300 mg per day) or empagliflozin (25 mg per day) increases urinary glucose excretion by 60-90 g per day 289, 302, 303 . SGLT2 inhibitors are metabolized by uridine diphosphate glucuronosyl transferases, and no significant interactions with other drugs have been reported 289, 305, 306 .
Pharmacodynamics
Dapagliflozin. In a 24-week RCT 307 involving drug-naive patients with T2DM, compared with placebo, dapagliflozin 5-10 mg per day reduced HbA 1c by 0.8-0.9%, and reduced body weight by 2.8-3.2 kg. A meta-analysis 308 of RCTs of 12-104 weeks duration showed that dapagliflozin (2.5-10.0 mg per day) improved HbA 1c , FPG and weight compared with placebo when used as an add-on therapy to metformin, insulin, thiazolidinediones, sulfonylureas or metformin ± sitagliptin (mean difference between groups −0.52%, 95% CI −0.60% to −0.45%, −1.52 mmol/l, 95% CI −1.75 mmol/l to −1.29 mmol/l and −1.61 kg, 95% CI −1.97 kg to −1.26 kg, respectively). The reductions in HbA 1c and FPG compared with placebo were generally similar with different background treatments, but were greatest when dapagliflozin was added to a sulfonylurea (−0.96%, 95% CI −0.86% to −0.52% and −1.47 mmol/l, 95% CI −1.86 mmol/l to −1.08 mmol/l) 308 . The largest between-group difference in weight change was seen when dapagliflozin was added to insulin (−2.45 kg, 95% CI −2.99 kg to −1.92 kg) 308 . Dapagliflozin and glipizide were compared in a 52-week RCT with a 156-week extension 309 ; dapagliflozin resulted in lesser HbA 1c reductions in the initial 18-week titration phase, but the 18-104-week coefficient of failure was lower with dapagliflozin (0.13% per year) than with glipizide (0.59% per year). HbA 1c reductions were greater with dapagliflozin by week 104 (difference from glipizide −0.18%, 95% CI −0.33% to −0.03%, P = 0.021) 309 . Dapagliflozin also resulted in sustained reductions in weight and systolic blood pressure (104-week differences from glipizide −5.1 kg, 95% CI −5.7 kg to −4.4 kg and −3.9 mmHg, 95% CI −6.1 mmHg to −1.7 mmHg, respectively) 309 . In an RCT 310 involving 180 patients with T2DM inadequately controlled by metformin, a modest level of weight loss with dapagliflozin add-on compared with placebo was associated with significant improvements in health-related quality of life over 102 weeks. In an RCT 311 involving 18 men with T2DM, in comparison with placebo dapagliflozin resulted in increased glucagon secretion from as early as 1 h after administration, reaching a peak after 4 h. After 3 days of dapagliflozin treatment, the fasting plasma glucagon concentration was 32% higher than on day 1, compared with no change in the placebo group 311 . The increase in glucagon was associated with increased endogenous glucose production 311 . The mechanism underlying this apparently compensatory change is not known, although SGLT2 expression has been noted in pancreatic α cells 312 .
Canagliflozin.
In a meta-analysis of RCTs, canagliflozin was found to reduce HbA 1c when used as monotherapy (WMD −1.08%, 95% CI −1.25% to −0.90%, P <0.00001) or add-on treatment (−0.73%, 95% CI −0.84% to −0.61%, P <0.00001), compared with placebo 313 . Relative to active comparators, canagliflozin reduced HbA 1c by −0.21% (95% CI −0.33% to −0.08%, P = 0.001) 313 . Canagliflozin also reduced HbA 1c in comparison with sitagliptin (−0.24%, 95% CI −0.40% to −0.09%, P = 0.002) and glimepiride (−0.12%, 0.95% CI −0.23% to −0.01%, P = 0.03) 313 , and reduced FPG in comparison with placebo (−33.50 mg/dl, 95% CI −39.22 mg/dl to −27.78 mg/dl, P <0.00001) and active comparators (−15.86 mg/dl, 95% CI −23.17 mg/dl to −8.56 mg/dl, P <0.00001) 313 . Canagliflozin resulted in greater weight loss than placebo (−2.81 kg, 95% CI −3.26 kg to −2.37 kg) or active comparators (−3.49 kg, 95% CI −4.86 kg to −2.12 kg), particularly when compared with glimepiride (−5.40 kg, 95% CI −5.95 kg to −4.85 kg, P <0.00001) 313 . Addition of canagliflozin to insulin treatment (generally by a basal-bolus regimen) has been shown to result in a significant reduction in HbA 1c at 18 weeks (and sustained up to 52 weeks) compared with placebo, from a baseline of 8.3% (−0.62%, 95% CI −0.69% to −0.54%, P <0.001 with 100 mg canagliflozin and −0.73%, 95% CI −0.81% to −0.65%, P <0.001 with 300 mg canagliflozin) 314 . In an RCT involving 37 patients, following an initial dose of canagliflozin, a second dose of 300 mg canagliflozin administered immediately before a mixed-meal tolerance test reduced postprandial glucose (compared with placebo) without causing further increases in urinary glucose excretion, which suggests the induction of mechanisms such as SGLT1 inhibition in the gut 315 . 313 .
Empagliflozin. In 24-week RCTs [317] [318] [319] [320] , empagliflozin (as monotherapy or added to metformin, to metformin with sulfonylurea or to pioglitazone with or without metformin) resulted in reductions in HbA 1c , body weight and systolic blood pressure of 0.7-0.8%, 1.5-2.5 kg and 2.9-4.1 mmHg respectively, which were significant in comparison with placebo. Reductions in HbA 1c and weight were maintained in trial extensions up to 76 weeks [321] [322] [323] [324] . Compared with sitagliptin monotherapy for 24 weeks, empagliflozin monotherapy resulted in similar HbA 1c reductions, but greater reductions in FPG, body weight and systolic blood pressure 317 . Over 104 weeks, empagliflozin was noninferior to glimepiride as an add-on to metformin treatment, and resulted in less hypoglycaemia 325 . In patients receiving basal insulin (with or without the additional regimen of metformin with or without sulfonylurea), empagliflozin resulted in HbA 1c reduction of 2.0-2.5% compared with placebo over 78 weeks, along with 2.4-4.1 kg weight loss 326 . Addition of placebo, empagliflozin 10 mg or empagliflozin 25 mg to a multiple daily injection insulin regimen reduced HbA 1c (−0.81 ± 0.08%, −1.18 ± 0.08% and −1.27 ± 0.08%, respectively) after 52 weeks 327 . Insulin dose and body weight were reduced (by −9 to −11 international units per day and −2.4 kg to −2.5 kg, respectively) with empagliflozin treatment compared with placebo, without increasing the risk of hypoglycaemia 327 . In a 12-week RCT 328 of patients with T2DM, baseline systolic blood pressure of 130-159 mmHg and diastolic blood pressure of 80-99 mmHg, the adjusted mean difference versus placebo in change from baseline in mean 24-h systolic blood pressure was −4.16 mmHg (95% CI −5.50 mmHg to −2.83 mmHg), and in diastolic blood pressure was −1.72 mmHg (95% CI −2.51 mmHg to−0.93 mmHg) with 25 mg empagliflozin (both P <0.001).
Compared with placebo, empagliflozin resulted in an adjusted mean HbA 1c difference of −0.68% (95% CI −0.88% to −0.49%) in patients with eGFR 60-90 ml/ min/1.73 m 2 and −0.42% (95% CI −0.56% to −0.28%) in patients with eGFR 30-60 ml/min/1.73 m 2 over 24 weeks, and the treatment was well tolerated 329 .
Safety and adverse effects SGLT2 inhibitors are associated with low risk of hypoglycaemia except when used in combination with insulin or sulfonylureas 289 . This low risk reflects the ability of uninhibited SGLT2 (and SGLT1) to reabsorb all of a reduced filtered glucose load as the blood glucose level declines, emphasizing the self-limiting nature of this mode of action 289 . Compared with the sulfonylurea glipizide, dapagliflozin resulted in significantly lower risk of hypoglycaemia (4.2% versus 45.8%) in an RCT involving 814 patients with T2DM over 104 weeks 309 . Canagliflozin treatment was associated with similar rates of hypoglycaemia to placebo when used as monotherapy or as an add-on therapy, except when added to sulfonylurea (RR 1.49, 95% CI 1.14-1.95, P = 0.004) 313 . The percentage of patients having confirmed hypoglycaemic events with empagliflozin treatment has been shown to be <1% when used as monotherapy, 1.4-2.4% when used as add-on to metformin or pioglitazone, 11.5-16.1% when combined with sulfonylureas and 35-58% when added to insulin 28, 239, 305 . SGLT2 inhibitors are associated with increased risk of genital infections, but an increase in urinary tract infection (UTI) has not been consistently reported 289 . Compared with sulfonylureas, dapagliflozin has been associated with increased risk of genital and urinary tract infections (14.8% and 13.5%, respectively, with dapagliflozin, 2.9% and 9.1%, respectively, with glipizide) 309 . No increased risk of UTIs was observed in patients treated with canagliflozin, but the risk of genital tract infections was increased (RR 3.76, 95% CI 2.23-6.35, P <0.00001 versus placebo, RR 4.95, 95% CI 3.25-7.52, P <0.00001 versus active comparators); the increase was greater in women than in men, but none of the reported infections was severe and all were resolved with simple treatment 313 .
In a pooled analysis of RCTs 330 , genital mycotic infection occurred more commonly with canagliflozin 100 mg and 300 mg than with placebo in women (10.4%, 11.4% and 3.2%, respectively) and in men (4.2%, 3.7% and 0.6%, respectively). Similar results were found when canagliflozin was compared with active control (14.7%, 13.9% and 3.1% in women, 7.3%, 9.3% and 1.6% in men) 330 . The infections were generally mild and easy to treat, but laboratory confirmation was lacking for most events 330 . Similarly, a review of the properties of empagliflozin found an association with UTI in some trials, but not others, whereas all trials showed increased risk of genital infections 305 . SGLT2 inhibitors are associated with small increases in LDL cholesterol, but also corresponding increases in HDL cholesterol; these effects might be slightly greater with canagliflozin than with other SGLT2 inhibitors 313, 331 . Results differ with regard to the risk of osmotic diuresis and hypovolaemia 289, 332 . In a meta-analysis 313 , the risks of adverse effects related to osmotic diuresis were found to be higher with canagliflozin than with placebo (RR 3.93, 95% CI 2.25-6.86, P <0.00001) or active comparators (RR 2.57, 95% CI 1.26-5.25, P = 0.009), whereas volume-related adverse effects did not differ. In a 12-week RCT 333 , canagliflozin 300 mg resulted in decreased plasma volume at week 1 (−5.4% versus 4.3% with placebo, P = 0.02), along with a modest increase in urinary volume, both of which were attenuated by week 12. In a pooled analysis 334 of data from >11,000 patients with T2DM, empagliflozin was not associated with the frequency of events related to volume depletion, but a high frequency of such events occurred in patients ≥75 years of age receiving empagliflozin 25 mg, and in patients receiving loop diuretics in addition to empagliflozin 10 mg.
SGLT2 inhibitors, particularly canagliflozin, might have adverse effects on the risk of fractures. The results of an RCT 335 with dapagliflozin showed no effect on markers of bone formation or resorption, or bone mineral density after 50 weeks of treatment in men and postmenopausal women with T2DM inadequately controlled by metformin 334, 335 . However, in some studies, canagliflozin has been shown to affect levels of urinary calcium, serum phosphate and 1,25-dihydroxyvitamin D 336 . In a 26-week RCT 336 with a 78-week extension that included 716 patients with T2DM aged 55-80 years, canagliflozin treatment was associated with a decrease in total hip bone mineral density over 104 weeks (placebo-subtracted changes −0.9% and −1.2% for 100 mg and 300 mg canagliflozin, respectively), but no effect was seen at other bone sites. In a pooled analysis of eight studies (n = 5,867), the incidence of fractures was similar with (1.7%) and without (1.5%) canagliflozin (HR 1.09, 95% CI 0.71-1.66) 337 . Separate analysis of results from the CANVAS trial (n = 4,327) showed a significant increase in fractures with canagliflozin (4.0%) compared with placebo (2.6%; HR 1.51, 95% CI 1.04-2.19), as well as increased fallrelated adverse effects 337 . However, compared with the non-CANVAS trials, patients in the CANVAS trial were older (62.4 ± 8.0 years versus 57.6 ± 9.8 years), with a high risk of cardiovascular disease, and with lower baseline eGFR and higher diuretic use 337 . Several instances of euglycaemic and hyperglycaemic diabetic ketoacidosis have been reported in patients who received SGLT2 inhibitors [338] [339] [340] [341] . The diabetic ketoacidosis prevalence in 17,596 patients from randomized studies of canagliflozin was 0.07% (n = 12) 341 . Many of the affected patients, with T2DM treated with insulin, had reduced or stopped insulin or experienced an intercurrent illness that would increase the demand for glucose 342 . A lack of insulin leads to increased lipolysis and conversion of excess fatty acids to ketones, but the hyperglycaemia associated with SGLT2 inhibitors is typically mild, presumably because they reduce blood glucose 338, 339, 342 . In many of the occurrences of diabetic ketoacidosis, reduction of insulin dose revealed latent autoimmune diabetes of adults, a form of type 1 diabetes mellitus (T1DM). Other instances of diabetic ketoacidosis resulted from off-label use of SGLT2 inhibitors in patients with T1DM 338, 339, 342 . Patients treated with insulin and undertaking selfmonitoring of blood glucose should not, therefore, discontinue insulin when they observe a reduction in blood glucose after introduction of an SGLT2 inhibitor. The SGLT2 therapy can improve glycaemic control, but does not obviate the need for insulin.
Pooled analysis of the results of phase II and phase III trials suggests a beneficial effect of dapagliflozin on cardiovascular disease 65 . Cardiovascular outcomes in patients treated with SGLT2 inhibitors are being assessed in a number of RCTs. In a study of 7,020 patients with T2DM at high risk of cardiovascular events, occurrence of a composite end point of nonfatal myocardial infarction, nonfatal stroke and death from cardiovascular causes was lower with empagliflozin than placebo, in addition to standard therapy (HR 0.86, 95% CI, 0.74-0.99, P = 0.04 for superiority) 343 . Empagliflozin treatment also reduced the risk of cardiovascular death (HR 0.62, 95% CI, 0.49-0.77, P <0.001), death from any cause (HR 0.68, 95% CI, 0.57-0.82, P <0.001) and hospitalization from heart failure (HR 0.65, 95% CI, 0.50-0.85, P = 0.002) 343 . Subgroup analyses showed heterogeneity for the primary outcome; the benefits of empagliflozin were more evident in the Asian population, in patients with BMI <30 kg/m 2 and HbA 1c <8.5%, in those not on insulin treatment and in those with nephropathy 343 . The effect of empagliflozin on death from cardiovascular causes was consistent across all subgroups 343 . Results of other cardiovascular outcome trials with dapagliflozin and canagliflozin are awaited with interest.
Other agents Dopamine D 2 receptor agonists Bromocriptine quick release (QR) is a dopamine D 2 receptor agonist that is licensed in some countries outside Europe for treatment of T2DM as an adjunct to lifestyle changes 344, 345 . The effect of bromocriptine on glycaemic parameters has been noted since 1980 (REF. 346 ). The drug provides a morning boost to hypothalamic dopamine levels, consistent with normal diurnal glucoregulation, and contributing to a reduction of sympathetic tone, neural suppression of hepatic glucose production and improvement in peripheral glucose disposal, without affecting insulin levels 28, 344, 346, 347 . A meta-analysis showed that bromocriptine QR add-on therapy, compared with placebo, reduced levels of HbA 1c (−6.52 mmol/mol, 95% CI −8.07 mmol/mol to −4.97 mmol/mol) and FPG (−1.04 mmol/l, 95% CI −1.49 mmol/l to −0.59 mmol/l), but had no effect on postprandial glucose 348 . Bromocriptine QR was weight neutral and was not associated with the risk of hypoglycaemia, hypotension or cardiovascular effects 348 . However, bromocriptine QR increased gastrointestinal adverse effects of nausea and vomiting, relative to placebo 348 . In an RCT 349 involving 3,095 patients, bromocriptine QR (as monotherapy or add-on to glucoselowering agents, including insulin) was shown to reduce the risk of cardiovascular disease, compared with placebo (HR 0.60, 95% CI 0.35-0.96) by 52 weeks.
Bile-acid sequestrants
Bile-acid sequestrants are established treatments for dyslipidaemia and are associated with a reduction in the risk of cardiovascular disease 350 . In 2008, the FDA licensed colesevelam as an adjunct to lifestyle measures to improve glycaemic control in T2DM 26 . The mechanism of action might involve the passage of bile acids along the intestine, possibly activating bile-acid receptors on L cells, leading to secretion of GLP-1. Inhibiting the return of bile acids to the liver could also affect glucose metabolism by preventing activation of hepatic farnesoid receptors 28 . Colesevelam reduced HbA 1c by 0.30-0.54% compared with placebo, in combination with metformin, sulfonylureas, pioglitazone or insulin, with no increased risk of hypoglycaemia or weight gain 350, 351 . Despite its favourable effect on levels of LDL cholesterol and HDL cholesterol, colesevelam increased levels of triglycerides by 11-22% 350 .
Pramlintide
Pramlintide, a soluble analogue of islet amyloid polypeptide, was introduced in 2005 as an injectable mealtime adjunct to a basal-bolus insulin regimen 352 . It assists glycaemic control and weight control through a centrally-mediated effect via the area postrema, which activates neural pathways that enhance satiety, suppress pancreatic glucagon secretion and slow gastric emptying 352 . Modest reductions in HbA 1c , typically 0.3-0.6%, have been reported alongside body-weight reductions of 1-2 kg and reductions of the bolus insulin requirement 352 . Addition of pramlintide to treatment adds to the burden of mealtime injections and requires care with dose adjustments to minimize risks of nausea and hypoglycaemia 352 .
Treatment algorithm
The treatment options for patients with T2DM now extend to a variety of drug classes with different mechanisms of action, low risks of hypoglycaemia and favourable effects on body weight. The availability of several agents within most classes offers choice with regard to pharmacokinetics, pharmacodynamics and the timing and mode of delivery. However, direct comparisons can be difficult when long-term head-to-head studies are not available, as can determining suitability for individual patients in the absence of studies in particular patient subgroups. Overall, the choice of treatment must balance efficacy with safety, tolerability with adherence and budgets with resources, as well as considering practical issues relating to realistic targets, monitoring and life situations 36 . Metformin is firmly established as the preferred first-line pharmacotherapy in patients with T2DM 36 . Expectations are increasing for SGLT2 inhibitors, and the results of ongoing RCTs will help to determine the positioning of this class in the treatment algorithm. Notably, the choice of metformin as first-line therapy is mainly based on the results of the UKPDS, which included 342 patients assigned to metformin, whereas the efficacy of empagliflozin has been demonstrated in 4,687 patients in the EMPA-REG study 343 . The EMPA-REG study included patients with advanced disease and high risk of cardiovascular disease, whereas the UKPDS population had newly diagnosed T2DM. If HbA 1c targets are not met with metformin treatment within 3 months, the recommendation from the American Diabetes Association and the European Association for the Study of Diabetes is to add a differently-acting agent 36 . Although oral agents will often have similar efficacy, the injectables (GLP-1RAs and insulin) can have greater effects on HbA 1c 241 . However, efficacy is not just about HbA 1c , but must always take into account a 'package' of effects that includes risk of hypoglycaemia, weight gain, general tolerability and long-term safety. For example, the risks of weight gain and hypoglycaemia are higher with sulfonylureas and insulin than with DPP-4 inhibitors and SGLT2 inhibitors 36 . Thiazolidinediones have a low risk of hypoglycaemia, but increase body weight and the risks of heart failure and bone fractures, compared with placebo 36 . An individualised approach to treatment is important, taking into account patients' circumstances and needs. Therapeutic choice is restricted in people who drive, the elderly, the frail and those with renal, neural and other comorbidities.
If the addition of a second agent fails to achieve or maintain acceptable glycaemic control, adding a third differently acting agent can be indicated 36 . Most classes of agents can be combined with additive efficacy, although addition of DPP-4 inhibitors to GLP-1RAs is unlikely to offer extra control. If triple combinations are inadequate, introduction of insulin (usually basal initially with continued metformin) is needed. If basal insulin is insufficient, addition of meal-time insulin, a GLP-1RA or possibly an SGLT2 inhibitor can be considered 36 . Addition of a GLP-1RA in this context might be a useful treatment strategy, as it has less risk of hypoglycaemia than meal-time insulin, and has a better effect on weight.
The availability of increasing numbers of agents that are given at a frequency less than daily might be attractive for many patients, and might enhance compliance. The outcomes of ongoing cardiovascular safety studies could further clarify the T2DM treatment algorithm, as could the introduction of additional long-acting GLP-1RAs, DPP-4 inhibitors and SGLT2 inhibitors that are in development 18, 26, [353] [354] [355] [356] [357] .
Lessons for future therapies Advances in the understanding of the pathogenesis of T2DM have informed the development of different classes of treatments 358 . However, treatments are needed with longer lasting metabolic effects than those currently available, and with the ability to improve, or prevent continuing decline in, β-cell function. Clearly, safety is of paramount importance. Adverse effects have been found with several agents that have now been discontinued, highlighting the importance of maintaining pharmacovigilance. Minimizing hypoglycaemia, weight gain and cardiovascular events while avoiding any increased risk of cancer is crucial for new treatments, particularly as they might need to be taken for many years. In real life, medications will be used in more varied populations than in clinical trials, and they might be prescribed by less-specialized professionals to patients who will not receive the intensive follow-up and monitoring associated with RCTs 359 . When considering safety, it can be extremely difficult to interpret results from preclinical studies, or to have available the most appropriate models to decide which treatments should be developed further. Another challenge is to identify and interpret adverse signals in clinical trials for extrapolation to real life 359 . Faint signals from preregistration trials can take a decade or more to reveal their clinical importance and are often confounded by several biases, including treatment allocation and detection of complications. Pressure to ensure safety is increasing, but regulatory agencies have a difficult task to strike a balance between appropriate caution and making sure that new beneficial treatments are made available in a safe, but timely manner 359 . Understanding the factors responsible for variations in the responses of individuals to particular treatments, and the influence of pharmacogenetics on pharmacokinetics and efficacy will facilitate personalized and patient-centred therapies 29 .
Conclusion
Many different glucose-lowering therapies are now available to address different aspects of the pathogenesis of T2DM through a range of actions, and these treatments vary in efficacy, convenience, adverse effect profiles and cost. The potential 'value' of a therapy involves more than a cost-benefit analysis, and is based on a 'package' of attributes that takes account of long-term safety, tolerability, risk of hypoglycaemia and weight gain and suitability in the presence of comorbidities and other medications. Individualized therapy must be tailored to patients' needs and preferences, with consideration of their circumstances, understanding and commitment.
DPP-4 inhibitors, GLP-1RAs and SGLT2 inhibitors have low risks of hypoglycaemia (except when combined with insulin or sulfonylurea) and are associated with either weight loss or weight neutrality, but they are more expensive than older agents such as sulfonylureas and meglitinides. Evidence relating to the safety profiles of many of these newer agents is encouraging and suggests their value in the challenge to provide early, effective and sustained glycaemic control in T2DM. Although metformin remains the preferred initial pharmacotherapy (when tolerated), an individualized approach is required to assess treatment targets and to achieve them in the safest possible manner.
